Neoadjuvant tislelizumab plus chemotherapy among patients with locally advanced cervical cancer: A prospective, single-arm, phase II trial

被引：0
|
作者：
Sheng, Jindong [1 ]
Liu, Wenxin [1 ]
Liu, Ruoyan [1 ]
Liu, Chunyan [1 ]
Wang, Bochang [1 ]
Liu, Xiangyu [1 ]
Xu, Changxiao [1 ]
Fu, Xin [1 ]
Wang, Ke [1 ]
机构：
[1] Tianjin Med Univ, Tianjin, Peoples R China
来源：
GYNECOLOGIC ONCOLOGY | 2024年 / 190卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12
引用
收藏
页码：S14 / S14
页数：1
相关论文
共 50 条
  • [41] Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastroesophageal junction cancer: A prospective, single-arm, phase II clinical trial
    Zhang, P.
    Zhang, W.
    Liu, X.
    He, D.
    Yang, K.
    Gou, H.
    Hu, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S903 - S903
  • [42] Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
    Guo, Honghai
    Ding, Ping'an
    Sun, Chenyu
    Yang, Peigang
    Tian, Yuan
    Liu, Yang
    Lowe, Scott
    Bentley, Rachel
    Li, Yaru
    Zhang, Zhidong
    Wang, Dong
    Li, Yong
    Zhao, Qun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial
    Gong, Lei
    Yang, Yueyang
    Zhang, Hongdian
    Qiao, Yufeng
    Wang, Haitong
    Ren, Peng
    Tang, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
    Liu, Jun
    Yang, Yang
    Liu, Zhichao
    Fu, Xiaolong
    Cai, Xiaoyue
    Li, Hongxuan
    Zhu, Li
    Shen, Yan
    Zhang, Hong
    Sun, Yifeng
    Chen, Hezhong
    Yu, Bentong
    Zhang, Renquan
    Shao, Jinchen
    Zhang, Ming
    Li, Zhigang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
  • [45] The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial
    Huang, Nai-si
    Wei, Wen-jun
    Xiang, Jun
    Chen, Jia-ying
    Guan, Qing
    Lu, Zhong-wu
    Ma, Ben
    Sun, Guo-hua
    Wang, Yu-long
    Ji, Qing-hai
    Wang, Yu
    THYROID, 2021, 31 (12) : 1808 - 1813
  • [46] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
    Huang, X.
    Shen, J.
    Xiong, Y.
    Wang, Y.
    Cao, X.
    He, M.
    Zou, G.
    Deng, Y.
    Wang, X.
    Lan, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
  • [47] Efficacy and safety of tislelizumab plus anlotinib in the treatment of cervical cancer resistant to standard therapy: A prospective, single-arm, open labelled phase II clinical trial
    Zheng, M.
    Zhou, Y.
    Zhou, J.
    Jiang, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S806 - S806
  • [48] Camrelizumab plus concurrent chemoradiotherapy for locally advanced cervical cancer: Preliminary results of a single-arm, open-label, phase II trial
    Xiao, Y.
    Cheng, H.
    Wang, L.
    Yang, L.
    Yu, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S805 - S805
  • [49] Neoadjuvant tislelizumab plus chemotherapy followed by salvage surgery and adjuvant tislelizumab for recurrent head and neck squamous cell carcinoma after radiotherapy: A single-arm, phase II trial
    Wu, Wenjie
    Wang, Lin
    Zhang, Tong
    Zhang, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial
    Zhu, Jun
    Song, Chunyan
    Zheng, Zhong
    Xia, Lingfang
    Chen, Yanqiong
    Ke, Guihao
    Wu, Xiaohua
    FRONTIERS IN ONCOLOGY, 2021, 11
12345